【复星医药回应复宏汉霖私有化失败：将一如既往地支持复宏汉霖发展】金十数据1月22日讯，复星医药公告称，复宏汉霖私有化计划失败，复宏汉霖将保留H股上市地位。对此，复星医药向记者表示，公司对复宏汉霖私有化议案未能通过表示遗憾，也充分尊重所有股东决定，复星医药仍然是复宏汉霖的控股股东，将一如既往地支持复宏汉霖长期健康发展；此次复宏汉霖保留H股上市地位，也体现了投资人看好复宏汉霖以及生物医药产业的未来前景。复宏汉霖方面则表示，相关信息可参阅集团和企业的联合公告。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.